Drugs / LYL273
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05319314 | Aug 2022 → Jun 2028 expected | colorectal cancer | Lyell Immunopharma, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Lyell Immunopharma, Inc. | Results Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion lyell.com ↗
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxis |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-10 | Lyell Immunopharma, Inc. | Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer lyell.com ↗ |
| 2026-06-08 | Lyell Immunopharma, Inc. | Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion lyell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYL273 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05319314 ↗ |
| Modality | Cell therapy | “LYL273, a GCC-targeted CAR T-cell product candidate” NCT05319314 ↗ |
| Route | Intravenous | “Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)” NCT05319314 ↗ |